RecruitingPhase 3NCT05670951

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Sponsor

Elgan Pharma Ltd.

Enrollment

360 participants

Start Date

Feb 27, 2025

Study Type

INTERVENTIONAL

Conditions

Intestinal Malabsorption

Summary

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Eligibility

Min Age: 1 DayMax Age: 5 Days

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ELGN-2112 and a drug called Placebo for people with intestinal malabsorption. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Day to 5 Days.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGELGN-2112

Human insulin \[rDNA\]

DRUGPlacebo

Placebo

Locations(1)

Laniado Hospital

Netanya, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05670951

Related Trials

Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

NCT059046261 location